Fig. 3
From: EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia
Conditional knockdown of IL3RA impairs the engraftment of EP300-ZNF384-positive B-cell acute lymphoblastic leukemia (B-ALL) cells in mice. (A) The schematic diagram of the in vivo experiment. NALM-6 cells expressing EP300-ZNF384 or EP300-ZNF384 and shIL3RA were transplanted into immune-deficient NOD⁃PrkdcscidIl2rgnull mice. Mice were then treated with doxycycline (Dox, 2 mg/mL) in drinking water. After 20 d, four mice were sacrificed and femur bone marrow cells were collected for leukemia cell analysis. The remaining six mice were euthanized upon signs of disease. (B) Kaplan–Meier survival curve of mice injected with EP300-ZNF384 or EP300-ZNF384 and shIL3RA-expressing NALM-6 cells. **P < 0.01 (C) hCD19 fractions within the femur bone marrow of each mouse. (D) Column plots summarizing data from all animals analyzed as in C. ***P < 0.001. (E) Changes in the spleen in EP300-ZNF384-expressing NALM-6-transplantable mice in response to IL3RA knockdown. (F) Spleen weights are presented by column plots. ***P < 0.001. (G) The leukemic invasions in spleen and liver were analyzed by hematoxylin and eosin staining. Scale bar: 50 μm. (H) Wright–Giemsa staining of BM cells from mice with NALM-6 cells expressing EP300-ZNF384 or EP300-ZNF384 and shIL3RA. Scale bar: 20 μm